Vaccinations for people living with HIV: what is recommended and when

HIV primarily affects CD4+ T-cell numbers and function, which means people living with HIV (PLHIV) have a higher risk of severe outcomes from several vaccine-preventable infections. The Australian Immunisation Handbook and the ASHM HIV Management Guidelines set out a clear, individualised plan, coordinated with your HIV physician, that substantially reduces that risk while staying safe.

The CD4 rule, briefly

The single most important safety principle is around live attenuated vaccines. Under Australian guidelines:

• CD4 below 200 cells/μL, live vaccines are generally not given (MMR, varicella, yellow fever, BCG, oral typhoid, intranasal influenza).
• CD4 200–350 cells/μL, live vaccines are given with clinical judgement and specialist input.
• CD4 above 350 cells/μL and undetectable viral load, live vaccines are generally safe to give.

Inactivated, recombinant and subunit vaccines, the great majority, are safe to give at any CD4 count. Where possible, timing vaccinations after CD4 recovery on antiretroviral therapy produces a stronger response.

Recommended vaccinations

Inactivated and recombinant (safe at any CD4)

• Annual influenza, every year. Strongly recommended.
• Pneumococcal, both conjugate and polysaccharide doses, NIP-funded for PLHIV. Reduces invasive pneumococcal disease, which is several times more common in PLHIV.
• Hepatitis A and hepatitis B, complete course with post-vaccination serology to confirm immunity. Higher non-response rates in PLHIV mean some people need a four-dose schedule or higher-dose formulations.
• HPV vaccination, a three-dose schedule is recommended for PLHIV up to age 26 (and considered up to 45), regardless of CD4 count.
• Meningococcal ACWY and meningococcal B, indicated for PLHIV; check eligibility through your HIV clinic.
• dTpa (whooping cough booster) every 10 years, sooner around newborns or in pregnancy.
• COVID-19 boosters, per current ATAGI advice. PLHIV with CD4 below 200 or detectable viraemia are in the more frequent booster cohort.
• Recombinant shingles vaccine, two doses, recommended for adults with HIV from age 18. The recombinant formulation is non-live and preferred at any CD4 count.
• RSV (older adults), HIV infection is recognised as an immunocompromising condition associated with higher RSV-disease severity, vaccination is recommended in adults aged 60 and over.

Live vaccines (CD4-dependent)

• MMR, generally given if CD4 ≥200 and ideally ≥350; two doses, four weeks apart.
• Varicella (chickenpox), given at CD4 ≥200 with care; serology often used first to confirm whether vaccination is needed.
• Yellow fever, only at authorised Yellow Fever Vaccination Centres, with specialist input. Often given at CD4 ≥350; the certificate is required for travel to some countries.
• Oral typhoid and BCG, generally avoided in PLHIV; inactivated typhoid or no BCG is the usual approach.
• Live attenuated nasal-spray influenza, generally avoided; the standard inactivated injection is used instead.

Travel

Pre-travel vaccination plans for PLHIV need extra lead time, six to eight weeks where possible. Yellow fever, hepatitis A, typhoid, rabies, Japanese encephalitis and meningococcal ACWY are common considerations. We coordinate the plan with your HIV clinic and refer for yellow fever where the certificate is required.

Boosters and repeat dosing

Some vaccines need additional doses or shorter intervals in PLHIV to generate a durable response, hepatitis B is the clearest example. Serology testing four to eight weeks after the final dose confirms immunity and identifies the small number of people who need a second course.

What to coordinate with your HIV physician

• Current CD4 count and viral load, to determine which live vaccines are safe.
• Antiretroviral regimen, to time vaccinations after immune recovery where possible.
• Hepatitis B serology, to confirm whether you need vaccination and to plan post-vaccination testing.
• Travel plans, well in advance.

Privacy

Your HIV status is your information. We don’t require disclosure for routine vaccinations, but we do ask about immunocompromising conditions during the screening checklist to determine whether live vaccines are appropriate. You can share as much or as little detail as you want, in a private consultation room. Records are protected under the Privacy Act 1988 and the Health Records Act 2001 (Vic), see our Privacy Policy.